The ring trail aims at the evaluation of the entire process of the chromosome banding analysis in haematological neoplasias starting with the receipt of the sample and ending with the outgoing report.
Once per year.
A surrogate blood sample is generated by using cell lines. The sample is sent out with a fictitious request. The request includes a diagnostic question, which needs to be answered by a chromosome banding analysis.
The analysis has to be carried out according to the own laboratory standard operational procedures. For evaluation, the findings have to be submitted in a written diagnostic report.
Proof of target aberrations through chromosome banding analysis, correct karyotype, correct report of findings.
The identification of a defined target aberration is prerequisite to attest a successful participation in the EQA test.
A certificate will be provided that states the (successful) participation in the trial. The certificate is valid for two years.
EQA test supervisor
Prof. Dr. med. Harald Rieder Universitätsklinikum Düsseldorf, Institut für Humangenetik Universitätsstraße 1 40225 Düsseldorf
Dr. rer. nat. Karin Hardt Universitätsklinikum Düsseldorf, Institut für Humangenetik Universitätsstr. 1 40225 Düsseldorf
If you would like to contact the EQA test supervisor(s), please call or e-mail the Coordination Office QA of BVDH: